The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Fluarix 2026/2027
influenza virus vaccine · INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL · Suspension · Intramuscular · GlaxoSmithKline Biologicals SA
NDC 58160-0725-52 · 10 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA125127
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of influenza virus vaccine (Suspension)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| GlaxoSmithKline Biologicals SA | INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL | Jul 22, 2026 | Sep 2, 2026 |
| ID Biomedical Corporation of Quebec | INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR 278 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA A VIRUS A/MICHIGAN/105/2025 SAN 049A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA B VIRUS B/TOKYO/EIS13-175/2025 ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug/.5mL | Jul 22, 2026 | Sep 2, 2026 |
| GlaxoSmithKline Biologicals SA | INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL | Jul 15, 2026 | Jul 15, 2026 |
| ID Biomedical Corporation of Quebec | INFLUENZA A VIRUS A/MICHIGAN/105/2025 SAN 049A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR 278 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug/.5mL; INFLUENZA B VIRUS B/TOKYO/EIS13-175/2025 ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug/.5mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Fluarix 2026/2027 — NDC 58160-0725-52," retrieved September 3, 2026, https://drugdashboards.com/drug/58160072552.
Free to cite with attribution — see how the data is put together.